CJC-1295 No DAC

Ipamorelin (co-supplied)

Mechanism of Action

CJC-1295 No DAC is a synthetic analogue of GHRH(1-29), modified at four amino acid positions to resist DPP-IV enzymatic cleavage. It selectively binds the GHRH receptor on pituitary somatotroph cells, stimulating intracellular cAMP via Gαs-coupled signaling and driving pulsatile growth hormone (GH) secretion.

Ipamorelin acts via selective agonism of GHS-R1a (ghrelin receptor) through a Gαq-coupled IP3/DAG pathway, independent of the GHRH receptor. Noted in research for minimal effect on cortisol and prolactin secretion compared to earlier GH secretagogues.

When studied in combination, the two peptides produce additive or synergistic GH secretory responses by engaging both the GHRH-axis and ghrelin-axis simultaneously. Downstream, GH drives hepatic IGF-1 production via JAK2-STAT5 signaling, with IGF-1 acting through the IGF-1R/PI3K/Akt/mTOR pathway.

Research Applications

• GHRH receptor activation and pituitary GH secretion studies
• GHS-R1a (ghrelin receptor) agonism research (Ipamorelin component)
• Dual-axis GHRH/ghrelin synergy protocols in pituitary research models
• IGF-1 axis and downstream PI3K/Akt/mTOR signaling studies
• Pulsatile GH secretion pattern investigation
• DPP-IV stability and peptide half-life modification research

Peer-Reviewed References

1. Jetté L, et al. hGRF(1-29)-Albumin Bioconjugates: CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005;146(7):3052–3058.
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
3. Veldhuis JD, et al. Dual secretagogue drive of burst-like growth hormone secretion. J Clin Endocrinol Metab. 2001;86(12):5955–5963.

Testing & Supply Specifications

Every Blueprint Labs batch is independently verified by third-party analytical laboratories prior to release. Identity and purity confirmed via HPLC and mass spectrometry. Full batch records maintained for chain-of-custody traceability.

📄 View Certificate of Analysis